ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

A. Lindo Patterson: Pioneer and Mentor

October 26, 2021

In Brief: ASCO awards career development grants.

May 21, 2004

MD Anderson’s Balance Sheet is Issue No. 1 For DePinho’s “Moon Shots Program”

October 12, 2012

In Brief: Leonidas Platanias named director of Lurie Comprehensive Cancer Center

October 3, 2014

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014

HIPAA Interpretations Vary, Delay Research, ASCO Study Finds

July 31, 2009